| Biomarker ID | 1473 |
| PMID | 25075204 |
| Year | 2014 |
| Biomarker | CCND1 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.99 |
| Effect on Pathways | Pathways include: Myc repressed pathway, Chronic myeloid leukemia, Cyclin A-Cdk2-associated events at S phase entry, Melanoma, Viral myocarditis |
| Experiment | Lethal Outcome Vs No Lethal Outcome |
| Type of Biomarker | Prognostic |
| Cohort | 340 Prosteactomy samples were chosen in the cohort and divided into training and testing |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.036 |
| Method Used | Automated quantitative multiplex immunofluorescence in situ imaging |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |